# A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer

> **NCT00924209** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 7 (actual)

## Conditions studied

- NSCLC
- Stage IIIA (N2)

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Bevacizumab
- **PROCEDURE:** Surgery
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT00924209
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-03
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Study was terminated due to poor accrual.
- **Last updated:** 2018-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00924209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00924209, "A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00924209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*